A major breakthrough in obesity treatment has arrived in the U.S. with the Food and Drug Administration (FDA) approving a new weight‑loss pill that experts have called the “holy grail” of therapies.
The medication, branded Foundayo and developed by Eli Lilly, is a daily oral pill that targets appetite‑regulating pathways similar to popular injected drugs like Mounjaro and Wegovy.
Foundayo became the second FDA‑approved GLP‑1 weight‑loss pill, following another oral option approved late last year. Its clinical trial results showed that patients lost an average of more than 12 percent of their body weight over the study period.
Unlike many existing treatments that require injections, Foundayo is taken once a day by mouth and can be taken with or without food, offering convenience that may appeal to many people.
The drug was approved rapidly under an expedited FDA process, reflecting the agency’s emphasis on making effective obesity treatments available sooner.
Foundayo is intended for adults with obesity or adults who are overweight with at least one related health condition, and it is meant to be used alongside a reduced‑calorie diet and increased physical activity.
While the trial results are promising, GLP‑1 therapies can have side effects, including nausea, gastrointestinal issues, and serious warnings such as increased risk for certain thyroid tumors. Patients should consult a doctor before starting any new weight‑loss medication.
Foundayo’s approval marks a major shift in obesity treatment options, with oral medications now offering a competitive alternative to injectable therapies for many patients.
